Novartis to Host Stakeholder Dialogue on Access to Healthcare in Lower-Income Countries

The event will take place on November 21 in Basel.

The third Novartis Social Business stakeholder dialogue, co-hosted this year with Novartis Oncology, will bring together a cross-section of stakeholders in Basel on November 21. They will discuss opportunities and innovations that will define the future of access programs and social business models in developing countries.


The event will be an opportunity to reflect on how access models have helped deliver better healthcare for populations living at the base of the pyramid – including key hurdles and achievements, and how learnings can help define next steps. It will also provide perspectives on how innovative partnerships, inclusive business approaches, digital health, impact investment and local solutions can help shape the future of access to healthcare in lower-income countries.

Event details

Speakers and panelists will include a broad spectrum of representatives from patient groups, think tanks, private foundations and healthcare practitioners, including The Max Foundation, the Ethiopian Red Cross, FSG, Allied World Healthcare, Bamboo Capital Partners, the Cameroonian Society of Cardiology, the Medtronic Foundation, and the Myanmar Health and Development Consortium.

Jayasree K. Iyer, executive director of the Access to Medicine Foundation, and Raj Panjabi, co-founder and CEO of Last Mile Health and 2017 TED Prize winner, will also speak during the day.

Exploring the future of access to healthcare in lower-income countries: what will drive success?

November 21, 2017

09:30 – 15:30 CET

Basel, Novartis campus

Participation is free of charge but registration is required as places are limited.

Register for the eventDownload the agenda

A highlights video and full versions of each keynote speech and panel discussion will be made available shortly after the event.

Follow the discussion on twitter: #talkingNCDs

Novartis Social Business stakeholder dialogue events on access to healthcare

All our Novartis Social Business programs take a "learn by doing" approach as we look for new and better ways to expand access to healthcare in lower-income settings. As part of that, we are committed to transparency and dialogue – and our series of stakeholder events endeavors to do just that.

Find out more about the previous events:

Improving care for chronic patients in lower-income countries: the patient journey

Watch the recap | Read the summary

Partnering for impact: addressing the burden of noncommunicable diseases in lower-income countries 

Watch the recapRead the summary

Novartis Survey Uncovers Real-World Impact of Immune Thrombocytopenia or ITP, a Rare Blood Disease, on Patients' Quality of Life

Findings from more than 1,300 patients across 13 countries showed ITP had especially high impact for many patients on emotional well-being (36%) and ability to work (28%).

Originally Published by Novartis.

Many patients with the rare blood disorder immune thrombocytopenia (ITP) find the disease has a negative impact on their everyday quality of life, according to interim results of a Novartis survey, called I-WISh, presented today at the 23rd Congress of the European Hematology Association (EHA) in Stockholm, Sweden (Abstract #PF654).

Read More Show Less

Open Resources at Novartis Help Drive Innovation

With external help from Novartis, an Argentinian researcher was able to begin his search for a new medicine for tuberculosis.

Originally Published by Novartis.

By K.E.D. Coan

"Back in Argentina, you never think of going for a real drug, but coming to Novartis completely changed what I thought was possible," says Bernardo Bazet Lyonnet, a postdoctoral researcher who first came to Novartis in 2016 as a Next Generation Scientist ( NGS). This program invites talented scientists from around the world for a bi-directional learning exchange at the Novartis campus in Basel, Switzerland.

Read More Show Less

Third Novartis Phase III trial shows Kisqali combination therapy significantly improves PFS in HR+/HER2- advanced breast cancer

"In the advanced breast cancer setting, it is important to ensure we provide patients with treatment options that increase time to disease progression while also maintaining quality of life."

Originally Published by Novartis.

Novartis announced positive results from the third Phase III trial of Kisqali® (ribociclib) in advanced or metastatic breast cancer. MONALEESA-3 showed Kisqali plus fulvestrant significantly prolonged progression-free survival (PFS) compared to fulvestrant alone in postmenopausal women with hormone-receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced breast cancer. MONALEESA-3 is the largest phase III trial to evaluate efficacy and safety of a CDK4/6 inhibitor plus fulvestrant in multiple advanced breast cancer patient populations - first-line and second-line settings[1]. These data will be presented as an oral presentation at the 54th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago (Abstract #1000) and published simultaneously in the Journal of Clinical Oncology.

Read More Show Less